
Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Your AI-Trained Oncology Knowledge Connection!


Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the phase III DUO trial, a randomized comparison of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia.

Published: February 28th 2018 | Updated:

Published: May 14th 2021 | Updated: